Ci3-Project “Health economic evaluation of IVAC-Immunotherapy”
BioNTech in Mainz is developing with support of the Federal Ministry of Education and Research (BMBF) individualized vaccines against cancer (IVACs) using tumor-specific information combined with RNA-platform technologies to tailor each patient‘s personalized immunotherapy for therapy of breast cancer. IVAC targets genetic alterations which are common to all known malignant cancer diseases, making this immunotherapeutic approach in principal applicable to all cancer indications. The IVAC concept is based on the fast assessment of the individual patient’s genome, subsequent identification of tumor-specific mutations and design and production of RNA-based vaccines tailored to the individual patient’s tumor mutanome. The aim of the health economic project is to perform cost-analyses and cost-effectiveness-analyses to provide evidence regarding the costs and utility of IVAC for patients and policy decision makers.
Funded by the Federal Ministry of Education and Research (BMBF)